Cyberonics (CYBX) 425 Business combination disclosure

Filed by Sorin S.p.A.

pursuant to Rule 425 under the United States Securities Act of 1933, as amended

Subject Companies: Sorin S.p.A., Cyberonics, Inc. and LivaNova PLC

Date: September 10, 2015

This filing relates to a proposed business combination involving

Sorin S.p.A., Cyberonics, Inc. and LivaNova PLC

(Subject Company Commission File No.: 000-19806;

Commission File No. for Registration Statement on Form S-4: 333-203510)

CREATING LIVANOVA, A PREMIER GLOBAL

MEDICAL TECHNOLOGY COMPANY

Important

Information

for

Investors

and

Shareholders

This

presentation

is

for

informational

purposes

only

and

is

not

intended

to

and

does

not

constitute

an

offer

to

sell

or

the

solicitation

of

an

offer

to

subscribe

for

or

buy

or

an

invitation

to

purchase

or

subscribe

for

any

securities

or

the

solicitation

of

any

vote

in

any

jurisdiction

pursuant

to

the

proposed

merger

transactions

involving

Cyberonics

Inc.

(“Cyberonics”),

LivaNova

PLC

(“LivaNova”)

and

Sorin

S.p.A.

(“Sorin”)

or

otherwise,

nor

shall

there

be

any

sale,

issuance

or

transfer

of

securities

in

any

jurisdiction

in

contravention

of

applicable

law.

No

offer

of

securities

shall

be

made

except

by

means

of

a

prospectus

meeting

the

requirements

of

Section

10

of

the

Securities

Act

of

1933,

as

amended,

and

applicable

European

regulations.

Subject

to

certain

exceptions

to

be

approved

by

the

relevant

regulators

or

certain

facts

to

be

ascertained,

the

public

offer

will

not

be

made

directly

or

indirectly,

in

or

into

any

jurisdiction

where

to

do

so

would

constitute

a

violation

of

the

laws

of

such

jurisdiction,

or

by

use

of

the

mails

or

by

any

means

or

instrumentality

(including

without

limitation,

facsimile

transmission,

telephone

and

the

internet)

of

interstate

or

foreign

commerce,

or

any

facility

of

a

national

securities

exchange,

of

any

such

jurisdiction.

This

communication

does

not

represent

a

public

offering

in

Italy,

pursuant

to

Section

1,

letter

(t)

of

Legislative

Decree

no.

58

of

February

24,

1998,

as

amended.

LivaNova

has

filed

with

the

Securities

and

Exchange

Commission

(the

“SEC”)

a

registration

statement

on

Form

S-4,

which

includes

a

proxy

statement

of

Cyberonics

that

also

constitutes

a

prospectus

of

LivaNova

(the

“proxy

statement/prospectus”).

The

registration

statement

on

Form

S-4

was

declared

effective

by

the

SEC

on

August

19,

2015,

and

a

definitive

proxy

statement/prospectus

will

be

delivered

as

required

by

applicable

law.

INVESTORS

AND

SHAREHOLDERS

ARE

URGED

TO

READ

THE

DEFINITIVE

PROXY

STATEMENT/PROSPECTUS

AND

OTHER

RELEVANT

DOCUMENTS

FILED

OR

TO

BE

FILED

WITH

THE

SEC,

CAREFULLY

AND

IN

THEIR

ENTIRETY,

WHEN

THEY

BECOME

AVAILABLE

BECAUSE

THEY

WILL

CONTAIN

IMPORTANT

INFORMATION

ABOUT

SORIN,

CYBERONICS,

LIVANOVA,

THE

PROPOSED

MERGER

TRANSACTIONS

INVOLVING

CYBERONICS,

SORIN

AND

LIVANOVA

AND

RELATED

MATTERS.

Investors

and

shareholders

are

able

to

obtain

free

copies

of

the

definitive

proxy

statement/prospectus

and

other

documents

filed

with

the

SEC

by

the

parties

through

the

website

maintained

by

the

SEC

at

www.sec.gov.

In

addition,

investors

and

shareholders

are

able

to

obtain

free

copies

of

the

definitive

proxy

statement/prospectus

and

other

documents

filed

with

the

SEC

(1)

on

Cyberonics’

website

at

www.cyberonics.com

within

the

“Investor

Relations”

section

or

by

contacting

Cyberonics’

Investor

Relations

(for

documents

made

available

to

Cyberonics’

shareholders)

or

(2)

on

Sorin’s

website

at

www.sorin.com

(for

documents

made

available

to

Sorin’s

shareholders).

The

presentation,

publication

or

distribution

of

this

presentation

in

certain

jurisdictions

may

be

restricted

by

law,

and

therefore

persons

in

such

jurisdictions

into

which

this

presentation

is

released,

published

or

distributed

should

inform

themselves

about

and

observe

such

restrictions.

Italian

CONSOB

Regulation

No.

11971

of

May

14,

1999

Prior

to

the

extraordinary

meeting

of

Sorin

shareholders,

Sorin

has

voluntarily

made

available

an

information

document

pursuant

to

Article

70,

paragraph

6,

of

the

CONSOB

Regulation

on

Issuers

(CONSOB

Regulation

no.

11971

of

May

14,

1999,

as

amended),

in

accordance

with

applicable

terms.

Italian

CONSOB

Regulation

No.

17221

of

March

10,

2010

Pursuant

to

Article

6

of

the

CONSOB

Regulation

no.

17221

of

March

12,

2010

(as

amended,

the

“CONSOB

Regulation”),

LivaNova

is

a

related

party

of

Sorin,

being

a

wholly

owned

subsidiary

of

Sorin.

The

merger

agreement

providing

for

the

terms

and

conditions

of

the

transaction,

which

exceeds

the

thresholds

for

“significant

transactions”

pursuant

to

the

Regulation,

was

approved

unanimously

by

the

board

of

directors

of

Sorin.

The

merger

agreement

and

the

merger

of

Sorin

into

LivaNova

are

subject

to

the

exemption

set

forth

in

Article

14

of

the

CONSOB

Regulation

and

Article

13.1.(v)

of

the

“Procedura

per

operazioni

con

parti

correlate”

(“Procedures

for

transactions

with

related

parties”)

adopted

by

Sorin

on

October

26,

2010

and

published

on

its

website

(www.sorin.com).

Pursuant

to

this

exemption,

Sorin

has

not

and

will

not

publish

an

information

document

(documento

informativo)

for

related

party

transactions

as

provided

by

Article

5

of

the

CONSOB

Regulation.

Participants

in

the

Distribution

Sorin,

Cyberonics

and

LivaNova

and

their

respective

directors

and

executive

officers

may

be

deemed

to

be

participants

in

the

solicitation

of

proxies

from

the

shareholders

of

Cyberonics

with

respect

to

the

proposed

transactions

contemplated

by

the

proxy

statement/prospectus.

Information

regarding

the

persons

who

are,

under

the

rules

of

the

SEC,

participants

in

the

solicitation

of

proxies

from

the

shareholders

of

Cyberonics

in

connection

with

the

proposed

transactions,

including

a

description

of

their

direct

or

indirect

interests,

on

account

of

security

holdings

or

otherwise,

is

set

forth

in

the

definitive

proxy

statement/prospectus

filed

with

the

SEC.

Information

regarding

Cyberonics’

directors

and

executive

officers

is

contained

in

Cyberonics’

Annual

Report

on

Form

10-K

for

the

fiscal

year

ended

on

April

24,

2015,

as

amended

from

time

to

time,

which

is

filed

with

the

SEC

and

can

be

obtained

free

of

charge

from

the

sources

indicated

above.

Safe

harbor

statement

This

presentation

contains

forward-looking

statements

within

the

meaning

of

Section

27A

of

the

Securities

Act

of

1933,

as

amended

and

Section

21E

of

the

Securities

Exchange

Act

of

1934,

as

amended.

These

statements

can

be

identified

by

the

use

of

forward-

looking

terminology,

including

"may,"

"believe,"

"will,"

"expect,"

"anticipate,"

"estimate,"

"plan,"

"intend,"

"forecast,"

or

other

similar

words.

Statements

contained

in

this

presentation

are

based

on

information

presently

available

to

Cyberonics,

Sorin

and

LivaNova

and

assumptions

that

the

parties

believe

to

be

reasonable.

Cyberonics,

Sorin

and

LivaNova

are

not

assuming

any

duty

to

update

this

information

if

those

facts

change

or

if

the

assumptions

are

no

longer

believed

to

be

reasonable.

Investors

are

cautioned

that

all

such

statements

involve

risks

and

uncertainties,

including

without

limitation,

statements

concerning

conducting

our

special

meeting

of

stockholders

and

closing

the

proposed

merger

transactions

involving

Cyberonics,

Sorin

and

LivaNova.

Important

factors

that

may

cause

actual

results

to

differ

include,

but

are

not

limited

to:

the

failure

to

obtain

applicable

regulatory

or

shareholder

approvals

in

a

timely

manner

or

otherwise,

or

the

requirement

to

accept

conditions

that

could

reduce

the

anticipated

benefits

of

the

proposed

transactions

as

a

condition

to

obtaining

regulatory

approvals;

the

failure

to

satisfy

other

closing

conditions

to

the

proposed

transactions;

the

length

of

time

necessary

to

consummate

the

proposed

transactions,

which

may

be

longer

than

anticipated

for

various

reasons;

risks

that

the

new

businesses

will

not

be

integrated

successfully

or

that

the

combined

companies

will

not

realize

estimated

cost

savings,

value

of

certain

tax

assets,

synergies

and

growth,

or

that

such

benefits

may

take

longer

to

realize

than

expected;

the

inability

of

Cyberonics,

Sorin

and

LivaNova

to

meet

expectations

regarding

the

timing,

completion

and

accounting

and

tax

treatments

with

respect

to

the

proposed

transactions;

risks

relating

to

unanticipated

costs

of

integration,

including

operating

costs,

customer

loss

or

business

disruption

being

greater

than

expected;

reductions

in

customer

spending,

a

slowdown

in

customer

payments

and

changes

in

customer

demand

for

products

and

services;

unanticipated

changes

relating

to

competitive

factors

in

the

industries

in

which

the

companies

operate;

the

ability

to

hire

and

retain

key

personnel;

the

potential

impact

of

announcement

or

consummation

of

the

proposed

transactions

on

relationships

with

third

parties,

including

customers,

employees

and

competitors;

the

ability

to

attract

new

customers

and

retain

existing

customers

in

the

manner

anticipated;

reliance

on

and

integration

of

information

technology

systems;

changes

in

legislation

or

governmental

regulations

affecting

the

companies;

international,

national

or

local

economic,

social

or

political

conditions

that

could

adversely

affect

the

companies

or

their

customers;

conditions

in

the

credit

markets;

risks

to

the

industries

in

which

Cyberonics,

Sorin

and

LivaNova

operate

that

are

described

in

the

“Risk

Factors”

section

of

the

Annual

Reports

on

Form

10-K,

Quarterly

Reports

on

Form

10-Q

and

other

documents

filed

from

time

to

time

with

the

SEC

by

Cyberonics

and

LivaNova

and

the

analogous

section

from

Sorin’s

annual

reports

and

other

documents

filed

from

time

to

time

with

the

Italian

financial

market

regulator

(CONSOB)

by

Sorin;

risks

associated

with

assumptions

the

parties

make

in

connection

with

the

parties’

critical

accounting

estimates

and

legal

proceedings;

the

parties’

international

operations,

which

are

subject

to

the

risks

of

currency

fluctuations

and

foreign

exchange

controls;

and

the

potential

of

international

unrest,

economic

downturn

or

effects

of

currencies,

tax

assessments,

tax

adjustments,

anticipated

tax

rates,

raw

material

costs

or

availability,

benefit

or

retirement

plan

costs,

or

other

regulatory

compliance

costs.

The

foregoing

list

of

factors

is

not

exhaustive.

You

should

carefully

consider

the

foregoing

factors

and

the

other

risks

and

uncertainties

that

affect

the

parties’

businesses,

including

those

described

in

Cyberonics’

Annual

Report

on

Form

10-K,

as

amended

from

time

to

time,

Quarterly

Reports

on

Form

10-Q,

Current

Reports

on

Form

8-K

and

other

documents

filed

from

time

to

time

with

the

SEC

by

Cyberonics

and

LivaNova

and

those

described

in

Sorin’s

annual

reports,

registration

documents

and

other

documents

filed

from

time

to

time

with

CONSOB

by

Sorin.

Nothing

in

this

presentation

is

intended,

or

is

to

be

construed,

as

a

profit

forecast

or

to

be

interpreted

to

mean

that

earnings

per

Sorin

share

or

Cyberonics

share

for

the

current

or

any

future

financial

years

or

those

of

the

combined

group,

will

necessarily

match

or

exceed

the

historical

published

earnings

per

Sorin

share

or

Cyberonics

share,

as

applicable.

None

of

Cyberonics,

Sorin

and

LivaNova

gives

any

assurance

(1)

that

any

of

Cyberonics,

Sorin

or

LivaNova

will

achieve

its

expectations,

or

(2)

concerning

any

result

or

the

timing

thereof,

in

each

case,

with

respect

to

any

regulatory

action,

administrative

proceedings,

government

investigations,

litigation,

warning

letters,

consent

decree,

cost

reductions,

business

strategies,

earnings

or

revenue

trends

or

future

financial

results.

Disclaimer / Safe Harbor Statement

2

•

Diverse, market-leading product portfolio to drive shareholder value

•

Technical and commercial scale across geographies to enhance revenue growth

•

Focused innovation platform to exploit market opportunities and accelerate product development in Heart

Failure, Sleep Apnea and Percutaneous Mitral Valve to improve patient outcomes

•

All-stock

transaction

resulting

in

pro

forma

combined

equity

value

of

approximately

$3.2

billion 

•

Transaction

expected

to

drive

cash

flow

generation

and

be

cash

EPS

accretive

to

all

shareholders

from

2016

Sorin Group and Cyberonics Inc. to create LivaNova, a leading

global medical technology company

3

1)

Based

on

the

closing

share

price

of

Sorin

Group

and

Cyberonics

on

31

August

2015.

Market

capitalizations

translated

at

€/$

exchange

rate

of

31

August

2015.

2)

Cash

EPS

based

on

US

GAAP,

excluding

transaction

related

expenses,

purchase

accounting

and

stock

based

compensation

expenses.

Calculated

on

a

fully

diluted

basis

1

2

Compelling strategic rationale

Leadership in Large and

Growing Markets

Opportunities in Three     

Multi-Billion Dollar

Specialty Markets

Global Scale and

Geographic

Diversification

Highly Complementary

Technologies

Strong Balance Sheet to

Execute Plan

4

FY

revenues

Cyberonics

and Sorin

at a glance

5

1)

FY

2015

figures

as

of

April

24   ,

2015

for

Cyberonics.

FY

2014

figures

as

of

December

31

2014

for

Sorin

translated

at

an

average

exchange

rate

of

$1.33/€1

Sutureless

valve

(Perceval

)

and

Goal-

Directed-Perfusion system

CRT

optimization

system

(SonR

)

Neuromodulation

for Heart Failure (HF)

Central Sleep Apnea

Percutaneous mitral valves

Emerging markets expansion

Growth

Platforms

Neuromodulation

for Heart Failure (HF)

Closed-loop neuromodulation

(AspireSR®)

Obstructive Sleep Apnea

Remote monitoring and seizure detection

$292m

$998m

Manufacturing

Facilities

2

10

Employees

~650

~3,900

Leader in devices for epilepsy and

neuromodulation

pioneer

Global leader in Cardiac Surgery and

leading innovator in CRM

Market

Leadership

1

TM

TM

st

th

Global scale and geographical diversification

São Paulo, Brazil

Cyberonics

Manufacturing and

offices

Sorin

Manufacturing and R&D

Vancouver, BC

Denver, CO

Houston, TX

Costa Rica

Mirandola, Italy

Meylan,

France

Saluggia, Italy

Munich, Germany

Clamart, France

Louvain-la-Neuve, Belgium

Dominican

Republic

Cantù, Italy

Suzhou, China

LivaNova

Business Unit Headquarters

6

Joint venture, China

Brussels

Highly complementary businesses …

1)

FY 2015 figures as of April 24th 2015 for Cyberonics. FY 2014 figures as of 31st December 2014 for Sorin translated at an average exchange rate of $1.33/€1

Geography

Business Unit

7

Revenues  :  $292m

Neuromodulation

100%

International

19%

US

81%

Revenues 

:  $998m

International

77%

US

23%

Cardiac

Surgery

67%

CRM

33%

1

1

Europe

43%

US

36%

Rest of

World

21%

$1.3bn

...leading to diversified product portfolio and broader

geographical reach

Pro

forma

revenues

by

geography

Pro

forma

revenues

by

business

8

1)

FY 2015 figures as of April 24th 2015 for Cyberonics. FY 2014 figures as of 31st December 2014 for Sorin translated at an average exchange rate of $1.33/€1

$1.3bn

Neuromodulation

23%

CRM

25%

Cardiac

Surgery

52%

1

1

•

Bringing together global leaders in Cardiac Surgery and Neuromodulation

•

Leveraging an innovative Cardiac Rhythm Management platform

Leadership in large and growing markets

CARDIAC

SURGERY

NEUROMODULATION

CRM

Cardiopulmonary global

leader

–

#1 in Heart-lung

machines

–

#1 in Oxygenators

Leading player in

mechanical and tissue

valves

On-going roll out of new

products

Long-standing leader in

Neuromodulation

#1 position in devices for

epilepsy

–

FDA approval for

AspireSR®

Pioneer in VNS treatment for

heart failure

–

CE Mark for VITARIA 

Leading innovator in CRM

–

Strong position in Europe

and Japan

–

Innovative products

focused on patient

outcomes

–

Robust pipeline

9

TM

Highly complementary technologies and selling capabilities

10

Shared technologies

Complementary commercialization capabilities

Implantable electronics

Neuromodulation

Heart Failure

Sleep Apnea

CRM

Wireless

MRI-Compatibility

Remote

Monitoring

ICD

Leads

VNS Science

and Expertise

Algorithms

Closed-

loop

Cardiac Surgeons

Electrophysiologists

HF Cardiologists

Perfusionists

Epileptologists

Neurologists

Neurosurgeons

Market development skills

Patient awareness & physician

education

Selling in competitive markets

Global footprint

Rechargeable

•

Accelerated development and commercialization of new product categories

•

The combined opportunities leverage Cyberonics’ ability to develop markets and

Sorin’s

geographical reach

Opportunities in billion dollar specialty markets

11

Heart

Failure (HF)

Sleep Apnea

Percutaneous Mitral

Potential market opportunity

> $1

billion

> $1

billion

> $1

billion

Cyberonics

programs

VITARIA™

Investment in ImThera

Ownership

of Apnex

assets and

IP (OSA)

-

Sorin

programs

EquiliaTM

Intense

Investment in Respicardia

(CSA)

Investments

in

Caisson,

HighLife,

Cardiosolutions

Timing of earliest

European

market entry

2015

2015

2017

Commentary

Creates

broad portfolio

strength, technological

expertise and market

development potential

Dual path

approach with

opportunities in large and under-

addressed Central and

Obstructive Sleep Apnea markets

Programs in both

Percutaneous

Mitral Repair

and Replacement

~$80 million of annual pre-tax operating synergies to be delivered by the end of 2018

Operating synergies driving significant incremental value

Manufacturing

Cyberonics’ leverage of Sorin’s

commercialization network

Neuromodulation

revenue

Capitalizing on market relationships with wider product range

Heart failure

Building an efficient corporate structure

Corporate overhead

Optimizing clinical trials for Heart Failure; building on technology assets, in

particular micro-electronic design, wireless technology and MRI-compatibility

R&D optimization

12

Purchasing savings and improved manufacturing overhead utilization

Experienced, world-class management team

13

André-Michel Ballester

Chief Executive Officer

Dan Moore

Non-Executive Chairman

of the Board

Ed Andrle

Strategy, Business Development

and New Ventures/Emerging

Therapies

Brian Sheridan

General Counsel

Pritpal

Shinmar

Global Market Access

David Wise

HR & IT

Demetrio Mauro

Chief Integration Officer

Michel Darnaud

Head of Cardiac

Surgery

Stefano Di Lullo

Head of Cardiac Rhythm

Management

Rohan Hoare

Head of

Neuromodulation

Jacques Gutedel

Head of

Intercontinental

Greg Browne

Interim Chief

Financial Officer

Transaction overview

14

LivaNova

PLC domicile and listing

•

Incorporated in the UK and UK tax

resident

•

Dual listed on Nasdaq and London Stock

Exchange

Exchange ratio

•

1:1 of LivaNova

stock for Cyberonics

shareholders

•

0.0472:1 of LivaNova

stock for Sorin

shareholders

Ownership

•

Cyberonics shareholders: ~ 54%

•

Sorin shareholders: ~ 46%

Governance

•

Dan Moore (Cyberonics) will be Non-

Executive Chairman

•

André-Michel Ballester (Sorin) will be CEO

•

Board of Directors equally balanced

(4 by Sorin, 4 by Cyberonics and 1 jointly

selected)

Key milestones achieved

15

Next steps

Transaction timeline: closing expected in Q4 2015

Unanimous approval by BoD

and deal

announcement

26 Feb

US Antitrust approval

14 April

LivaNova

management and integration team

announced

12 May

Sorin

EGM approved proposed merger

26 May

End of 15-day Sorin Shareholder Withdrawal

Right period

12 June

End of 60-day Sorin Creditor Rights period

27 July

Cyberonics stockholders meeting

22 September

Submission of listing application with NASDAQ

& approval of UK LivaNova

prospectus by

UKLA

Joint application to the UK Court & formal

listing submission to LSE

LivaNova

shares begin trading on Nasdaq &

LSE

Driving significant shareholder returns

Revenue growth

acceleration

•

Stronger and more diversified platform for growth

•

Significant revenue potential from highly complementary Heart

Failure programs

•

Leverage Sorin’s

commercialization network for Neuromodulation

Synergies

•

Approximately $80 million annual pre-tax operating synergies by

2018

•

R&D optimization, manufacturing & supply chain and overlapping

corporate costs

EPS impact

•

Cash

EPS

accretive

for

all

shareholders

from

2016

•

Significant EPS accretion thereafter

Balance Sheet

implications

•

Compelling financial profile with robust cash flow generation

•

Pro forma net debt position close to zero

16

1)

Cash

EPS

based

on

US

GAAP,

excluding

transaction

related

expenses,

purchase

accounting

and

stock

based

compensation

expenses.

Calculated

on

a

fully-diluted

basis

1

Sorin

Q2 2015 Results*

Ended June 30, 2015

17

•

Robust revenue growth in Cardiac Surgery (€146.7m, +5.5%°)

–

Strong momentum in cardiopulmonary

•

Solid results in Cardiac Rhythm Management (€68.3m, +4.6%°)

–

Growth in Low-Voltage

•

Successful roll-out of Inspire    in Europe, the US and Japan

•

Launch of FlexTherm   , ultimate generation of heating and cooling systems

•

Perceval    ’s approval in Canada and dedicated reimbursement status in Australia

•

Launch of KORA    250, the world’s smallest full-body MRI compatible pacemaker, in Europe

Value

Change

Revenues

€215.6m

+5.2%°

Gross Profit

€121.6m

+10.1%

EBITDA

€32.7m

+14.3%

Adjusted net profit*

€16.5m

+47.0%

°

At comparable foreign exchange rates

*

Adjusted

net

profit:

net

profit

before

after-tax

non-recurring

income

and

expenses

(special

items).

Details

are

available

in

Sorin’s

2015

second

quarter

results

press

release

dated

July

30,

2015

(see

www.sorin.com)

TM

TM

TM

TM

Cyberonics

Q1 2016 Results*

Ended July 24, 2015

18

•

Record net sales of $81m over the quarter

•

Record U.S. net product sales of $67.7m (+15%)

•

Driven by very strong demand for the AspireSR® generator

•

International net sales up 11.4% on a constant currency basis

•

Initial launch of Vitaria™ progressing well

Value

Change

Net Sales

$81.0m

+14.4%

Gross Profit

$71.6m

+8.4%

Adjusted EBITDA

$32.4m

+19.7%

Adjusted non-GAAP income

$27.8m

+26.4%

*Reconciliations between GAAP and non-GAAP financial measures are available in Cyberonics’ fiscal 2016 first quarter results press release dated August 20, 2015 (see www.cyberonics.com)

Contacts

19

FOR SORIN GROUP:

Investors:

Demetrio Mauro

CFO

Sorin

Group

Tel: +39 02 69969 512

e-mail: investor.relations@sorin.com

Francesca Rambaudi

Director, Investor Relations

Sorin

Group

Tel: +39 02 69969 716

e-mail: investor.relations@sorin.com

Media:

Gabriele Mazzoletti

Director, Corporate Communications

Sorin Group

Tel: +39 02 69969 785

e-mail: corporate.communications@sorin.com

Edward Simpkins

Finsbury (London)

Tel: +44 7947 740 551

e-mail: edward.simpkins@finsbury.com

Kal

Goldberg

Finsbury (New York)

Tel: +1 646 805 2000

e-mail: Kal.Goldberg@finsbury.com

FOR CYBERONICS, INC.:

Investors:

Greg Browne

CFO

Cyberonics, Inc.

Tel: +1 281 228 7262

e-mail: ir@cyberonics.com

Media:

Sard

Verbinnen

& Co

New York: 

Andrew Cole / Chris Kittredge

Tel: +1 212 687 8080

London:

Conrad Harrington

+44 020 3178 8914